Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2022-09-01 Board/Management Inform…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Retirement
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the retirement of two directors of the company following the 44th Annual General Meeting. It details the cessation of directorship due to retirement by rotation and non-reappointment, including dates and reasons. There is no financial data, audit information, or report content. The document is an announcement about changes in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, not a report or presentation.
2022-09-01 English
Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is dated August 30, 2022, and is addressed to stock exchanges with references to the 44th Annual General Meeting (AGM) of Gland Pharma Limited held on the same date. It contains detailed voting results and a combined scrutinizer's report as required under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content focuses on the official announcement of voting outcomes and the scrutinizer's report related to the AGM. There is no indication that this document is the full AGM presentation or materials, nor is it an annual report or financial statement. The document is not a report publication announcement but the actual voting results and related report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (15,000 characters) supports that it is a substantive announcement rather than a brief notice.
2022-08-30 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Investor Presentation Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events and information. The content is about informing the exchanges and public about upcoming investor meetings, which is a typical investor relations activity. There is no financial data, no report attached or referenced as being published, and no mention of earnings or management changes. This type of document is best classified as an Investor Presentation (IP) update or announcement. However, since it is only a schedule notification without detailed presentation content, it aligns more closely with an Investor Presentation (IP) category as it relates to investor communications and meetings. Confidence is high due to clear mention of analyst/investor meetings and regulatory citation for disclosure.
2022-08-30 English
Annual General Meeting
AGM Information Classification · 95% confidence The document is a detailed communication dated August 30, 2022, addressed to stock exchanges and shareholders, describing the proceedings of the 44th Annual General Meeting (AGM) of Gland Pharma Limited. It includes speeches by the Chairman and the Managing Director & CEO, covering business performance, strategic priorities, financial highlights, board changes, and ESG initiatives. The content is comprehensive and includes financial figures, business strategy, and operational updates typically presented at an AGM. The document is not merely an announcement of the AGM or a brief summary but contains substantive information shared during the AGM itself. Therefore, it fits the category of AGM Information (AGM-R).
2022-08-30 English
Newspaper Advertisements
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a newspaper advertisement published to inform shareholders. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 47, which pertains to public notices and advertisements. The document includes no financial data, no detailed report content, and is very short (1541 characters). It is an announcement of a shareholder communication (newspaper advertisement) rather than the report or advertisement content itself. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-08-27 English
Communication to shareholders as per Reg 30
AGM Information Classification · 95% confidence The document is an official communication from Gland Pharma Limited dated August 26, 2022, addressed to stock exchanges and shareholders. It informs about the 44th Annual General Meeting (AGM) scheduled for August 30, 2022, and details regarding e-voting procedures, including the voting items and changes in director reappointments. The content focuses on the AGM notice and voting instructions rather than the AGM report or minutes themselves. The document length is 6276 characters, which is relatively short and primarily serves as an intimation or notice related to the AGM. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related notices.
2022-08-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.